JP2022501345A5 - - Google Patents

Info

Publication number
JP2022501345A5
JP2022501345A5 JP2021514976A JP2021514976A JP2022501345A5 JP 2022501345 A5 JP2022501345 A5 JP 2022501345A5 JP 2021514976 A JP2021514976 A JP 2021514976A JP 2021514976 A JP2021514976 A JP 2021514976A JP 2022501345 A5 JP2022501345 A5 JP 2022501345A5
Authority
JP
Japan
Prior art keywords
wax
composition according
composition
semi
perfluorobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514976A
Other languages
English (en)
Japanese (ja)
Other versions
JP7360452B2 (ja
JP2022501345A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/075345 external-priority patent/WO2020064549A1/en
Publication of JP2022501345A publication Critical patent/JP2022501345A/ja
Publication of JP2022501345A5 publication Critical patent/JP2022501345A5/ja
Application granted granted Critical
Publication of JP7360452B2 publication Critical patent/JP7360452B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514976A 2018-09-27 2019-09-20 脂質バリアの修復 Active JP7360452B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18197200 2018-09-27
EP18197200.1 2018-09-27
PCT/EP2019/075345 WO2020064549A1 (en) 2018-09-27 2019-09-20 Lipid barrier repair

Publications (3)

Publication Number Publication Date
JP2022501345A JP2022501345A (ja) 2022-01-06
JP2022501345A5 true JP2022501345A5 (cg-RX-API-DMAC7.html) 2022-09-28
JP7360452B2 JP7360452B2 (ja) 2023-10-12

Family

ID=63685885

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514976A Active JP7360452B2 (ja) 2018-09-27 2019-09-20 脂質バリアの修復

Country Status (6)

Country Link
US (1) US12029757B2 (cg-RX-API-DMAC7.html)
EP (1) EP3856124A1 (cg-RX-API-DMAC7.html)
JP (1) JP7360452B2 (cg-RX-API-DMAC7.html)
KR (1) KR102808092B1 (cg-RX-API-DMAC7.html)
CN (1) CN112839620A (cg-RX-API-DMAC7.html)
WO (1) WO2020064549A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6039145B2 (ja) 2011-05-25 2016-12-07 ノバリック ゲーエムベーハー 半フッ化アルカンを基礎にした局所薬学的組成物
MX381639B (es) 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11510855B2 (en) 2018-09-27 2022-11-29 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
CN114449999A (zh) 2019-09-06 2022-05-06 诺瓦利克有限责任公司 用于治疗葡萄膜炎的眼用组合物
EP3861857A1 (en) * 2020-02-07 2021-08-11 Novaliq GmbH Antiparasitic compositions
WO2026037894A1 (en) * 2024-08-15 2026-02-19 Dermaliq Therapeutics, Inc. Semifluorinated alkane compositions for cleaning the skin
WO2026104414A1 (en) * 2024-11-12 2026-05-21 Dermaliq Therapeutics Gmbh Topical compositions for the treatment of alopecia areata

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
JPS5721312A (en) * 1980-07-12 1982-02-04 Green Cross Corp:The Breathable ointment
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPH0764702B2 (ja) 1986-04-23 1995-07-12 鐘紡株式会社 多相乳化型化粧料
JPH03279323A (ja) 1989-12-15 1991-12-10 Johnson & Johnson Consumer Prod Inc 日焼け止め組成物
JP3046346B2 (ja) 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
DE4405627A1 (de) * 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
RU2111738C1 (ru) 1996-06-24 1998-05-27 Акционерное общество "НИЗАР" Средство для усиления солнцезащитной активности фотозащитных агентов
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
CA2278328C (en) 1998-02-09 2008-07-22 Macrochem Corporation Antifungal nail lacquer and method using same
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
EP1152749B1 (en) 1999-02-08 2006-04-12 ALZA Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
US20060204458A1 (en) 2000-10-26 2006-09-14 Holloway William D Jr Anti-aging methods and composition
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
DE10042412B4 (de) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
WO2002089849A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
US20040265362A1 (en) 2001-09-04 2004-12-30 Rudy Susilo Plaster for the treatment of dysfunctions and disorders of nail growth
JP2005523252A (ja) 2002-01-26 2005-08-04 マイクロ サイエンス テック コーポレーション リミテッド 牧丹皮抽出物を有効成分として含む組成物
EP1663148A2 (en) 2003-08-25 2006-06-07 Foamix Ltd. Penetrating pharmaceutical foam
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
CA2538856C (en) 2003-10-10 2010-06-29 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
CA2540621A1 (en) 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US20080019926A1 (en) 2004-04-19 2008-01-24 Marie-Pierre Krafft Lung Surfactant Supplements
EP1763336A1 (en) 2004-06-08 2007-03-21 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005050431A1 (de) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
AU2008300013A1 (en) 2007-09-07 2009-03-19 Qlt Inc. Drug cores for sustained release of therapeutic agents
PL2110126T3 (pl) 2008-04-18 2012-04-30 Novaliq Gmbh Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej
PT2387391T (pt) 2009-07-24 2017-04-20 Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh Processo para o desenvolvimento de uma composição líquida a ser aplicada na forma de espuma sobre a pele e composição de aplicação tópica
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
HUP1000362A2 (en) 2010-07-12 2012-11-28 Egis Gyogyszergyar Nyrt Antiseptic and disinfecting compositions having reduced iodine content
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US20120100183A1 (en) * 2010-10-23 2012-04-26 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EP2661280B1 (en) 2011-01-04 2018-11-21 Novaliq GmbH O/w-emulsions comprising semifluorinated alkanes
US20120219640A1 (en) 2011-02-25 2012-08-30 Wright Kenneth W Anti-infective solution for athlete's foot
JP6039145B2 (ja) * 2011-05-25 2016-12-07 ノバリック ゲーエムベーハー 半フッ化アルカンを基礎にした局所薬学的組成物
CN103561724B (zh) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
PT2806886T (pt) 2012-01-23 2017-03-24 Novaliq Gmbh Composições de proteínas estabilizadas baseadas em alcanos semifluorados
JP2015520230A (ja) * 2012-06-25 2015-07-16 バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC アキシチニブを含んでいる眼科用局所医薬組成物
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
US9186305B1 (en) 2014-05-19 2015-11-17 Shiseido Company, Ltd. Sunscreen products in which excessive whiteness due to titanium dioxide and zinc oxide is visually masked upon skin application
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
US10668010B2 (en) 2016-06-08 2020-06-02 Majda Ficko Sun block formulation
DK3442480T3 (da) 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
CN106176937A (zh) * 2016-08-24 2016-12-07 刘艺鹏 湿疹、痤疮软膏
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US20210069014A1 (en) 2017-05-06 2021-03-11 Novaliq Gmbh Drop dispenser
US11510855B2 (en) 2018-09-27 2022-11-29 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
CN113164609A (zh) 2018-11-27 2021-07-23 诺瓦利克有限责任公司 包含ω-3脂肪酸乙酯的半氟化烷烃组合物
EP3861857A1 (en) 2020-02-07 2021-08-11 Novaliq GmbH Antiparasitic compositions

Similar Documents

Publication Publication Date Title
JP7360452B2 (ja) 脂質バリアの修復
US5503825A (en) Lip balm composition
JP5548456B2 (ja) 少なくとも1種のレチノイドおよび過酸化ベンゾイルを含むクリームゲル
JP2023154020A5 (cg-RX-API-DMAC7.html)
JP2022501343A5 (cg-RX-API-DMAC7.html)
CN105997613A (zh) 一种敏感修复型卸妆油及其制备方法
HU227318B1 (en) Cosmetical and dematological composition for treating, grooming of psoric skin and scalp
JPS6330884B2 (cg-RX-API-DMAC7.html)
BRPI1004113A2 (pt) composiÇço de peràxido de benzoÍla para tratamento de pele
JPH09501942A (ja) 石油ゼリークリーム剤
WO2000048567A1 (en) Method and composition for treating acne
HUE026388T2 (en) A combination comprising pyrrolidone-5-carboxylic acid and at least one compound selected from citrulline, arginine, and asparagine, and use in the treatment of atopic dermatitis
EP1603517B1 (en) Skin care product containing tall oil fatty acids and vegetable oils for dry and scaling skin and treatment of psoriasis, dermatitis, and eczemas
JP2015530380A (ja) 乾癬を治療するための組成物
ES2360469T3 (es) Composición farmacéutica que comprende un ungüento oleaginoso y dos principios activos en forma solubilizada.
US10028927B2 (en) Topical pharmaceutical formulation
JP5808140B2 (ja) 睫毛用化粧料
US6277362B1 (en) After shave treatment preparation
ES2880437T3 (es) Nuevas composiciones tópicas que comprenden ácido úsnico y su uso terapéutico
US8372440B2 (en) Antifungal foam containing ciclopiroxolamine and zinc pyrithione and medical and cosmetic applications thereof
JP2022509240A5 (cg-RX-API-DMAC7.html)
KR20140132005A (ko) 여드름 치료 방법 및 항-여드름 제형
BR102025009212A2 (pt) Uso de uma composição cosmética para manutenção e/ou restauração do microbioma do couro cabeludo
TW202241396A (zh) 醫藥品
Balm Soothing Calendula Lip Balm Recipe